In conclusion, the present report describes the successful re-introduction of a HER2-targeted ADC combined with a PD-1 inhibitor in a patient with recurrent HER2-positive breast cancer whose disease progressed upon treatment with similar ADCs. Here, ERBB2 is linked to breast cancer.